No, the dispersion index on that slide 12 says noting about cognition.
That slide is strictly only about Exposure and Dose (PK) as as statistical test on the small n=32 sample to see if it might be representative of A2-73 PK in the general AD population.
As always before, the data and results from every clinical test of blarcamesine, even Phase 1 and Phase 2 trials, are accurately predictive of subsequent Phase 3 trials. The data from the big Phase 3 Alzheimer's clinical trial are going to be exceptionally positive.